Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells $4,689,085.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $564.95, for a total value of $4,689,085.00. Following the completion of the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $25,519,921.40. This trade represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $541.70 on Friday. The stock’s fifty day moving average is $510.30 and its 200 day moving average is $539.65. United Therapeutics Corporation has a fifty-two week low of $409.07 and a fifty-two week high of $609.35. The firm has a market capitalization of $23.23 billion, a PE ratio of 19.38, a PEG ratio of 2.72 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same period in the previous year, the firm earned $6.41 earnings per share. United Therapeutics’s quarterly revenue was down 1.9% compared to the same quarter last year. Equities analysts forecast that United Therapeutics Corporation will post 26.21 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Callan Family Office LLC purchased a new position in shares of United Therapeutics in the second quarter valued at approximately $1,217,000. Nicholas Investment Partners LP raised its stake in United Therapeutics by 478.5% in the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock valued at $2,218,000 after purchasing an additional 3,766 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in United Therapeutics in the 2nd quarter valued at $3,359,000. Havemeyer Place LP acquired a new stake in United Therapeutics during the 4th quarter worth $2,189,000. Finally, Seven Fleet Capital Management LP acquired a new stake in United Therapeutics during the 4th quarter worth $633,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on UTHR. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Cantor Fitzgerald reiterated an “overweight” rating on shares of United Therapeutics in a report on Thursday. JPMorgan Chase & Co. raised their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Bank of America dropped their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Finally, Royal Bank Of Canada lowered their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $621.00.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: A Delaware federal court ruled that Liquidia’s Yutrepia infringes two United Therapeutics patents covering inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The court also rejected Liquidia’s arguments that the patents were invalid, strengthening the competitive position of United Therapeutics’ Tyvaso franchise. United Therapeutics prevails in patent litigation
• Positive Sentiment: The decision could limit Yutrepia’s use in the PH-ILD market and may support United Therapeutics’ request for FDA action requiring labeling that excludes the disputed indication. Investors view the ruling as potentially extending Tyvaso’s market protection and supporting future cash flow. UTHR prevails in Yutrepia patent dispute
• Neutral Sentiment: The ruling may still face appeals, additional legal proceedings, or regulatory delays, so the timing and ultimate commercial benefit remain uncertain. Analyst opinions are mixed, with some bullish targets but at least one notably bearish view, creating potential volatility. Analysts have conflicting sentiments on healthcare companies
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.5 million on October 1, following another 9,500 shares sold over the prior two days. EVP Paul Mahon also sold 8,300 shares for approximately $4.7 million. The transactions may reflect scheduled selling, but the concentration of insider sales can weigh on sentiment after the stock’s sharp advance. United Therapeutics insider selling

About United Therapeutics

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.